Down 31% in 3 months while the S&P 500 fell 5%.
−1Long-term trend
MGTX's Quality Score rose 2 points on Fri, Nov 6, to 5. It closed near its high of the day (2 chart checks started).
Follow MGTX's trial news. Pro members can get an alert when MeiraGTx Holdings files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 13.4% more shares than a year ago |
| Latest filing | 8-K, Sep 23 |
ReportExpected to report Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It fell after 4 of its last 4 reports, -2.1% on average. Past reports ›
After its last 4 reports it closed -2.1% on average, higher 0 of 4 times.
CFO Richard Giroux sold 56,000 shares on Oct 20, under a planned sale. 8 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
MGTX is #78 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 78 |
Expected to report Thu Nov 12, before the open (in 3 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase of $204.6 million was due to revenue recognized for the licenses granted to Reogen for the AAV-GAD and AAV-BDNF programs and the AAV-GAD delivery device.”
MGTX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase of $101.2 million was due to the release of deferred revenue from the termination of the original asset purchase agreement and supply agreement with J&J and the development and transition services provided to Reogen Limited (Reogen), formerly known as Hologen Neuro AI Limited, under the Hologen collaboration agreement and related agreements, which was partially offset by decreased activity of PPQ services under the original asset purchase agreement and related agreements with J&J as the work was substantially completed in the first half of 2025.”
From its results filing (SEC filing · Aug 13)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 13, 2026 | +9.5% | -2.2% | +15.5% |
| May 14, 2026 | +0.1% | -0.2% | -3.9% |
| Mar 26, 2026 | +0.3% | -1.2% | +19.3% |
Sales grew every year from 2023 to 2025, to $81.4M. It lost money in each of the three years.
RSI 38.2, MACD above signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
“The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property.”
MGTX scores 5 today, which Breakaway calls Below Average. It is #78 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 31% in 3 months while the S&P 500 fell 5%. Shares: 13.4% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MGTX scores 5 today, which Breakaway calls Below Average (0 to 5). That is #78 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MGTX's 5.
Expected to report Thu Nov 12, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. MGTX closed higher after 0 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.